Recalcitrant atopic dermatitis treated with omalizumab. - Wikidata - awgldk - TriplyDB

Recalcitrant atopic dermatitis treated with omalizumab.

Recalcitrant atopic dermatitis treated with omalizumab.

http://www.wikidata.org/entity/Q34050871

about

Most Highly Cytokinergic IgEs Have Polyreactivity to Autoantigens Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria Pathways to managing atopic dermatitis: consensus from the experts Systemic Treatment of Adult Atopic Dermatitis: A Review.Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis.Omalizumab: Anti-IgE therapy in allergy.The pathologic and clinical intersection of atopic and autoimmune disease.Anti-IgE--emerging opportunities for Omalizumab.Off-label prescriptions for atopic dermatitis in Europe.Off-Label Uses of Omalizumab.Omalizumab for atopic dermatitis: case series and a systematic review of the literature.

P2860

Q36341609-B352D3FC-2C43-4C47-ACF0-FA8C3180EADD Q37121967-0C9F9C16-AA1E-480C-A0BA-0AB98408FD16 Q37258723-3ABED5EA-CE21-47A2-B1F8-08E26A68A2D4 Q37679948-7E419B91-4FDA-4E8B-B334-29EAC6A5298A Q37709674-98255C0D-F215-4B7A-944D-F965175EC083 Q37829671-1AE91FE7-6224-48D5-9BD2-CABBE72A3C2E Q38035182-D793F62E-A765-4C92-B3E8-7BEBAEEC7DDF Q38091754-F969BC20-81A6-4410-A351-D3551FC7E2AA Q38235225-FDE45416-D38D-4B73-B5B4-7F90E82A5F4D Q38517653-AFB7B3E6-0F0F-442D-B3CC-2B59983E40A3 Q38874440-144E7B20-A7DD-4402-9590-973D5C716E04

P2860

Recalcitrant atopic dermatitis treated with omalizumab.

http://www.wikidata.org/entity/Q34050871

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Recalcitrant atopic dermatitis treated with omalizumab.

@ast

Recalcitrant atopic dermatitis treated with omalizumab.

@en

Recalcitrant atopic dermatitis treated with omalizumab.

@nl

type

label

Recalcitrant atopic dermatitis treated with omalizumab.

@ast

Recalcitrant atopic dermatitis treated with omalizumab.

@en

Recalcitrant atopic dermatitis treated with omalizumab.

@nl

prefLabel

Recalcitrant atopic dermatitis treated with omalizumab.

@ast

Recalcitrant atopic dermatitis treated with omalizumab.

@en

Recalcitrant atopic dermatitis treated with omalizumab.

@nl

P1433

Q34050871-AA26DACF-8D99-4526-B828-B00EFFBBE1DF

P1476

Q34050871-DBE705FF-EFDF-4B87-89B3-027B84E3ED3C

P2093

Q34050871-0AF4AD21-E434-4C65-8A9B-19BFC5BB28EB

Q34050871-35B48E32-728E-4673-94CC-2E10964F15C6

Q34050871-6E455203-A5DB-4F14-91E1-CA3401B9DAC1

Q34050871-9E922FAA-B438-4A64-90D9-CFAAF223C668

Q34050871-F796DF00-701A-4AF2-B979-4C1F38C68B7F

P2860

Q34050871-1C633527-6846-40C4-B8DE-524550EAEC2B

Q34050871-97EF718A-E98F-469B-8B7A-E3B4F4967B29

Q34050871-9B4A7DB2-8B23-4EF6-815E-04CECEDF3CEA

Q34050871-AF78CFDD-F1DD-4ED0-A87B-DC71BC68793A

Q34050871-FEAB464F-F9B1-447B-A32C-1E0EE8AC97AD

P304

Q34050871-B98ECED1-07C1-4756-9B03-F7ECEF5EC16A

P31

Q34050871-31d10bc4-5c96-435b-ae01-3060d2d629e5

Q34050871-6CEF6839-C719-48A9-8026-D3336769249B

P356

Q34050871-20E9D3D6-555A-41F6-9D83-7C5EE864E86A

P433

Q34050871-AF4AF27D-58CB-49E4-9D32-CCD0621A9931

P478

Q34050871-FC4CB9E7-D2A0-4ABD-B8E5-35895DC8755A

P50

Q34050871-B8242D91-ADBF-40A9-9C55-D63A116E4548

P577

Q34050871-E940172F-3867-4569-98B5-DB9CEB692BA8

P5875

Q34050871-BEECD6C0-85D1-4881-A926-9CDEA9EF95B7

P698

Q34050871-E718CE44-24B0-41A4-B7D7-A00DBE39DB4B

P932

Q34050871-C3B071CA-F125-4260-B135-B7F799C28283

P356

AD.2010.22.3.349

P1433

Annals of dermatology

P1476

Recalcitrant atopic dermatitis treated with omalizumab

@en

P2093

Chang-Hun Huh

http://www.w3.org/2001/XMLSchema#string

Jung-Im Na

http://www.w3.org/2001/XMLSchema#string

Kyoung-Chan Park

http://www.w3.org/2001/XMLSchema#string

Mi-Ra Choi

http://www.w3.org/2001/XMLSchema#string

Se-Young Park

http://www.w3.org/2001/XMLSchema#string

P2860

The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature.

Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report.

Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

Atopic Dermatitis

P304

349-352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5021/AD.2010.22.3.349

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Sang Woong Youn

P577

2010-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45651182

http://www.w3.org/2001/XMLSchema#string

P698

20711278

http://www.w3.org/2001/XMLSchema#string

P932

2917695

http://www.w3.org/2001/XMLSchema#string